Abacus Diagnostica Revenue and Competitors

Turku,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Abacus Diagnostica's estimated annual revenue is currently $155k per year.(i)
  • Abacus Diagnostica's estimated revenue per employee is $155,000

Employee Data

  • Abacus Diagnostica has 1 Employees.(i)
  • Abacus Diagnostica grew their employee count by 0% last year.

Abacus Diagnostica's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is Abacus Diagnostica?

Abacus Diagnostica Oy is a Finnish molecular diagnostic company, which has commercialized its proprietary GenomEra® platform. GenomEra CDX system has proven to be one of the fastest, easiest-to-use and the most cost-effective automated solution for molecular diagnostics (MDx) of infectious diseases. GenomEra is suitable also for small to mid-size customers without any prior experience in MDx. Abacus' vision is to provide cost-effective and easy-to-use products to enable MDx also in resource and capability limited settings.

keywords:N/A

N/A

Total Funding

1

Number of Employees

$155k

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Abacus Diagnostica News

2022-04-20 - MRSA Testing Market Size, Scope And Forecast | Leading ...

Becton Dickinson, Roche Diagnostics, 3M, Abacus Diagnostica, AdvanDX, Alere, Arlington Scientific, Atlas Genetics, Bio-Rad Laboratories,...

2022-04-17 - Infectious Disease Biomarker Testing Market Report Covers ...

... Disease Biomarker Testing Market Report Covers Future Trends With Research 2022 to 2029 – Abacus Diagnostica, ALPCO, Abbott Laboratories.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.6M40%N/A
#2
$0.7M9N/AN/A
#3
$1.1M11-21%N/A
#4
$1.4M13-13%N/A
#5
$1.6M1525%N/A